Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth S Cohen

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Nature Clinical Practice. Oncology|April 28, 2007
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancerChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Expert Review of Hematology|June 8, 2026
A call to action for the use of composite hematologic measurements in hereditary hemorrhagic telangiectasia and other chronic bleeding disordersHanny Al-Samkari, Raj S Kasthuri, Jenny Y Zhou, et al.
Circulation. Cardiovascular Genetics|April 16, 2011
Genetic and clinical correlates of early-outgrowth colony-forming unitsStanley Y Shaw, Susan Cheng, L Adrienne Cupples, et al.
Blood Advances|July 28, 2025
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCLKirk E Cahill, James K Godfrey, Chadi Nabhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Cancer Cell|January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
Nature Medicine|January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patientsChristopher G Willett, Yves Boucher, Dan G Duda, et al.
Cancer Research|October 27, 2012
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancersRifat Hasina, Nathan Mollberg, Ichiro Kawada, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Nature Clinical Practice. Oncology|April 28, 2007
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancerChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Expert Review of Hematology|June 8, 2026
A call to action for the use of composite hematologic measurements in hereditary hemorrhagic telangiectasia and other chronic bleeding disordersHanny Al-Samkari, Raj S Kasthuri, Jenny Y Zhou, et al.
Circulation. Cardiovascular Genetics|April 16, 2011
Genetic and clinical correlates of early-outgrowth colony-forming unitsStanley Y Shaw, Susan Cheng, L Adrienne Cupples, et al.
Blood Advances|July 28, 2025
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCLKirk E Cahill, James K Godfrey, Chadi Nabhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Cancer Cell|January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
Nature Medicine|January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patientsChristopher G Willett, Yves Boucher, Dan G Duda, et al.
Cancer Research|October 27, 2012
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancersRifat Hasina, Nathan Mollberg, Ichiro Kawada, et al.
Pageof 4